Thomas Haughey Sells 2,000 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the sale, the director owned 38,878 shares of the company’s stock, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ ANIP opened at $81.65 on Friday. The company has a 50 day simple moving average of $79.60 and a 200-day simple moving average of $79.41. The company has a market capitalization of $1.86 billion, a P/E ratio of 20.67 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a 1 year low of $61.17 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same quarter last year, the firm earned $1.70 EPS. The firm’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after buying an additional 27,598 shares during the period. State Street Corp boosted its position in ANI Pharmaceuticals by 2.2% in the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG boosted its position in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after buying an additional 91,153 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in ANI Pharmaceuticals by 8.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after buying an additional 43,523 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ANIP. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, June 1st. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.